Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
2000 1
2009 3
2011 2
2012 3
2013 9
2014 6
2015 9
2016 8
2017 5
2018 6
2019 3
2020 2
2021 8
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

55 results
Results by year
Filters applied: . Clear all
Page 1
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, Bykowski J, Ellison CA, Black LJ, Thompson PA, Callejas-Valera JL, Lee JH, Cohen EEW, Spanos WC. Powell SF, et al. Among authors: gold ka. J Clin Oncol. 2020 Jul 20;38(21):2427-2437. doi: 10.1200/JCO.19.03156. Epub 2020 Jun 1. J Clin Oncol. 2020. PMID: 32479189 Free PMC article. Clinical Trial.
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer.
Jänne PA, Baik C, Su WC, Johnson ML, Hayashi H, Nishio M, Kim DW, Koczywas M, Gold KA, Steuer CE, Murakami H, Yang JC, Kim SW, Vigliotti M, Shi R, Qi Z, Qiu Y, Zhao L, Sternberg D, Yu C, Yu HA. Jänne PA, et al. Among authors: gold ka. Cancer Discov. 2022 Jan;12(1):74-89. doi: 10.1158/2159-8290.CD-21-0715. Epub 2021 Sep 21. Cancer Discov. 2022. PMID: 34548309 Free article.
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI; study investigators. Shaw AT, et al. Among authors: gold ka. Lancet Oncol. 2016 Feb;17(2):234-242. doi: 10.1016/S1470-2045(15)00488-X. Epub 2015 Dec 19. Lancet Oncol. 2016. PMID: 26708155 Free PMC article. Clinical Trial.
3D Bioprinted Multicellular Vascular Models.
Gold KA, Saha B, Rajeeva Pandian NK, Walther BK, Palma JA, Jo J, Cooke JP, Jain A, Gaharwar AK. Gold KA, et al. Adv Healthc Mater. 2021 Nov;10(21):e2101141. doi: 10.1002/adhm.202101141. Epub 2021 Jul 26. Adv Healthc Mater. 2021. PMID: 34310082
Sleep and Breathing … and Cancer?
Owens RL, Gold KA, Gozal D, Peppard PE, Jun JC, Dannenberg AJ, Lippman SM, Malhotra A; UCSD Sleep and Cancer Symposium Group. Owens RL, et al. Among authors: gold ka. Cancer Prev Res (Phila). 2016 Nov;9(11):821-827. doi: 10.1158/1940-6207.CAPR-16-0092. Epub 2016 Sep 7. Cancer Prev Res (Phila). 2016. PMID: 27604751 Free PMC article. Review.
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R, Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ, Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Gettinger SN, et al. Among authors: gold ka. Lancet Oncol. 2016 Dec;17(12):1683-1696. doi: 10.1016/S1470-2045(16)30392-8. Epub 2016 Nov 8. Lancet Oncol. 2016. PMID: 27836716 Clinical Trial.
Nanoengineered Colloidal Inks for 3D Bioprinting.
Peak CW, Stein J, Gold KA, Gaharwar AK. Peak CW, et al. Among authors: gold ka. Langmuir. 2018 Jan 23;34(3):917-925. doi: 10.1021/acs.langmuir.7b02540. Epub 2017 Oct 25. Langmuir. 2018. PMID: 28981287
Sorafenib in non-small cell lung cancer.
Zhang J, Gold KA, Kim E. Zhang J, et al. Among authors: gold ka. Expert Opin Investig Drugs. 2012 Sep;21(9):1417-26. doi: 10.1517/13543784.2012.699039. Epub 2012 Jun 24. Expert Opin Investig Drugs. 2012. PMID: 22725255 Review.
55 results